| Schedule of basic and diluted net loss per share attributable to ordinary shareholders |
Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2026 | | Three Months Ended June 30, 2025 | | Loss Allocation | | Weighted Average Shares Outstanding | | Loss Per Share, Basic and Diluted | | Loss Allocation | | Weighted Average Shares Outstanding | | Loss Per Share, Basic and Diluted | | Ordinary Shares | $ | (22,689) | | | 30,532,234 | | | $ | (0.74) | | | $ | (19,004) | | | 3,856,925 | | | $ | (4.93) | | Company Series A Preferred Shares (1) | (2,148) | | | 2,890 | | | $ | (743.25) | | | (2,786) | | | 565 | | | $ | (4,930.97) | | | Net loss | $ | (24,837) | | | | | | | $ | (21,790) | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, 2026 | | Six Months Ended June 30, 2025 | | Loss Allocation | | Weighted Average Shares Outstanding | | Loss Per Share, Basic and Diluted | | Loss Allocation | | Weighted Average Shares Outstanding | | Loss Per Share, Basic and Diluted | | Ordinary Shares | $ | (43,951) | | | 30,465,395 | | | $ | (1.44) | | | $ | (32,904) | | | 2,331,339 | | | $ | (14.11) | | Company Series A Preferred Shares (1) | (4,169) | | | 2,890 | | | $ | (1,442.56) | | | (4,034) | | | 286 | | | $ | (14,104.90) | | | Net loss | $ | (48,120) | | | | | | | $ | (36,938) | | | | | |
(1) The weighted-average number of shares of as-converted Series A Preferred Shares used in the loss allocation was 2,890,000 for the three and six months ended June 30, 2026 and 565,435 and 285,824 for the three and six months ended June 30, 2025, respectively.
|
| Schedule of anti-dilutive net loss per share attributable to ordinary shareholders |
The potential ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have had an anti-dilutive effect were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2026 | | Six Months Ended June 30, 2026 | | Three Months Ended June 30, 2025 | | Six Months Ended June 30, 2025 | | Outstanding unvested restricted stock units | 561,170 | | 561,170 | | 438,386 | | 438,386 | | Outstanding unvested restricted stock awards | 67,271 | | 67,271 | | 118,864 | | 118,864 | | Outstanding and issued common stock options | 6,604,678 | | 6,604,678 | | 3,748,798 | | 3,748,798 | | Total | 7,233,119 | | 7,233,119 | | 4,306,048 | | 4,306,048 |
|